
Please try another search
Redx Pharma plc is a United Kingdom-based biotechnology company, which is focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease. The Company’s product pipeline includes RXC004 and ROC007. Its lead product candidate, RXC004, which is a potent and selective, orally active once-daily Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand driven cancer. RXC004 is in Phase I study in combination with nivolumab, an anti-PD1 antibody. The RXC007 is a selective and orally available small molecule inhibitor of Rho-Associated Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signaling pathway.
Name | Age | Since | Title |
---|---|---|---|
Jane Veronica Griffiths | 67 | 2021 | Independent Non-Executive Chair |
Robert Andrew Donald Scott | 68 | 2022 | Independent Non-Executive Director |
Natalie Brittenham Berner | 31 | 2021 | Shareholder Representative Non-Executive Director |
Lisa Mary Whewell Anson | 52 | 2018 | CEO & Executive Director |
Thomas Henry Burt | 42 | 2020 | Non-Executive Director |
Peter Presland | 72 | 2017 | Independent Non-Executive Director |
Bernhard Kirschbaum | 63 | 2016 | Independent Non-Executive Director |
Sarah L. Gordon Wild | - | 2020 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review